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RESPONSE: A QUEST AND A WAGER 
Rick Bevins, Ph.D., Paul Kenny, Ph.D., and Jed Rose, Ph.D.
Paul Kenny:  Dr. Markou’s paper is a good 
overview of where we are in the quest for 
new pharmacological treatments for smok-
ing addiction. The field is focusing mainly 
on the nicotinic receptors and the gluta-
mate and GABA neurotransmitter systems. 
The nicotinic receptors regulate the effects 
of nicotine, and through these receptors, 
nicotine brings both glutamate and GABA 
into play.
Jed Rose:  I think we are far from exploit-
ing the full potential of nicotine itself as a 
replacement for smoking. At present, fewer 
than 10 percent of people using nicotine 
replacement therapy (NRT) achieve long-
term smoking cessation. I think the success 
rate is low because we haven’t yet learned to 
administer nicotine in a way that reproduces 
the full effect of nicotine obtained from 
smoking. Along with acute reinforcement, 
stress reduction, and cognitive enhance-
ment, we also need to address the habit 
component—the constellation of sensory 
cues that develop around inhaling smoke.
Kenny:  Do you believe that it’s a viable 
strategy to consider medications that bypass 
the nicotinic receptor and instead work on 
other systems, like GABA and glutamate, 
that underlie the habitual aspects of smok-
ing behavior?
Rose:  Trying to modulate those down-
stream systems is an important strategy. 
However, I think it will likely be best used 
in combination with improved nicotine 
replacement. The difficulty of having a 
large impact on smoking without doing 
anything at the nicotine receptor should 
not be underestimated.
Rick Bevins:  Combining pharmacological 
treatments with behavioral approaches is a 
must. There may be a place for combining 
medications, for example, targeting reinforc-
ing effects with one and craving with another, 
or using one medication to alleviate the side 
effects of another. Such strategies are hinted 
at in the article but not addressed directly in 
a way that might encourage this approach.
Kenny:   It seems very logical to give people 
the safest therapeutic that we know works, 
which right now would be NRT. And 
then, it seems like a good idea to have as 
many tools as possible to try to help those 
people for whom NRT is less effective. 
So that’s where many of the compounds 
that the authors discuss come in, such as 
metabotropic glutamate receptor agonists 
or GABAB receptor agonists.
Bevins: The nicotine vaccine is another tool. 
One wouldn’t use it with NRT, of course, 
because it prevents nicotine from getting 
to the brain, but it makes a nice adjunct to 
non-nicotine treatments. It doesn’t have 
any central nervous system effects, so what 
you’re hoping it will do, at least in my mind, 
is just to catch people who slip and get them 
back on the abstinence track.
Rose:  I wouldn’t totally rule out the idea 
that there might be creative combinations 
of NRT and nicotine vaccine, perhaps in a 
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someone away from the smoking habit and 
then the latter to prevent its reestablish-
ment. In general, however, the nicotine 
vaccine and other treatments that prevent 
nicotine from activating nicotinic recep-
tors can help people partway, but not all 
the way, to long-term quitting. The reason 
is that these treatments don’t replace the 
nicotine effects that motivate most people 
to smoke—stress relief, enhanced pleasure, 
weight control, cognitive enhancement, 
and so forth.
Bevins:  A conundrum in treatment is that 
you want to reduce nicotine’s impact on 
glutamate and dopamine neurotransmis-
sion enough to block the drug’s motivating 
effects, but sustain enough neurotransmis-
sion to ward off symptoms of withdrawal. 
This is why it’s important to learn exactly 
what each compound does at the various 
nicotinic receptor subtypes. For example, 
varenicline (Chantix) seems to be effective 
because it stimulates some subtypes strongly 
but others in only a limited way.
Kenny:  Right. It’s all about balance. The 
therapeutic window you want to reach is the 
one in which you can control the person’s 
urge to smoke, but avoid the precipitation 
of withdrawal symptoms. 
The dosage of a compound can affect 
which receptor populations it strikes, and 
we have shown that this is true of nicotine as 
well. Nicotine at low doses activates the high-
affinity α4β2 and other receptor subtypes that 
are responsible for many of its pleasurable 
and other effects. At higher doses, the drug 
begins to hit α5-containing receptors in the 
habenula, which underlie aversive effects such 
as inhibition of reward systems.
Rose:  That observation has tremendous 
treatment potential. It suggests that one 
could get a very strong combination effect 
with a dual-action compound that activated 
the α4β2 receptors and also allosterically 
modulated the α5-containing receptors. The 
first action would relieve withdrawal and 
supply some of nicotine’s desirable effects, 
and the second action would trigger aversive 
effects if the individual smoked.
 
Kenny:  Yes. While nicotine’s effects on the 
nicotinic receptors and consequently on 
various neurotransmitter systems make sense 
as first places to look for an understanding 
of nicotine addiction, the drug also pro-
duces a large constellation of intracellular 
effects on signaling molecules and path-
ways. For example, nicotine can turn various 
kinases, phosphatases, and acetylases on or 
off. Hence, there are many other potential 
targets for therapeutic development within 
neurons. A further example of the poten-
tial of non-neurotransmitter, nonreceptor 
targets are the findings of George Uhl and 
other geneticists who are producing evidence 
that molecular processes classically thought 
to be involved in brain development are also 
implicated in addiction. 
As the field progresses in coming years, we 
will likely be looking for answers in domains 
of neuroscience that currently are not typi-
cally considered relevant to addiction.
A wager
AS&CP:  If you had $1,000 to bet on which 
strategy is going to bring the next large incre-
mental advance in smoking control, what 
would it be?
Rose:  I would put my money on the user-
friendly form of inhaled nicotine that we 
have been developing in my laboratory. We 
have shown that people can self-administer 
nicotine in a particle form that produces 
more satisfaction, less irritation, and more 
rapid rises in blood levels than they get from 
the currently available nicotine vapor sys-
tem. I think the impact on smoking rates 
will be dramatic. People will still be self-
administering nicotine, but most authorities 
believe that nicotine constitutes less than 10 
percent of the danger of smoking. I want to 
disclose a financial interest, because Philip 
Morris International just bought the patent 
rights to the approach. 
Bevins:  I’m going to bet on policy changes. 
For example, how about providing every-
one easy and inexpensive access to whatever 
antismoking intervention they want? The 
health care savings that we would gain by 
making the whole range of smoking ces-
sation interventions highly affordable and 
available would easily pay back the taxpayers.
Kenny:  I’m going to split my money into 
three $333 bets. First, I agree with Jed that 
nicotine and nicotine-like compounds have 
untapped promise. My own bias in this 
respect is for compounds that modulate 
the α5-containing receptors.
Second, there are other regulatory path-
ways that might produce breakthroughs. The 
authors discuss the GABA and glutamate 
pathways, but there are others. For example, 
Bill Corrigall has shown that the hypocre-
tin pathway has very profound effects on 
nicotine-seeking behavior in rodents.
Finally, there are entirely new directions 
that we might go in. Some medications that 
are already available for treating cancer, car-
diovascular disease, or diabetes may be effec-
tive for smoking. Some of these influence 
systems that there is currently no reason to 
believe might play a role in smoking, yet 
they may be central to the process.
We may already have a great compound 
out there. We just don’t know it yet.
Rose:  That raises an excellent point. We 
could potentially learn a great deal from 
clinical trials that are conducted on a wide 
range of conditions if they were to col-
lect information on smoking. It has been 
especially frustrating when clinical trials 
that test compounds for conditions that 
are highly associated with smoking, such 
as cocaine abuse, don’t measure the impact 
on smoking. After all, bupropion was devel-
oped because of the observation that people 
treated for depression reported changes in 
their smoking.